Loading clinical trials...
Loading clinical trials...
A Phase II Trial of FASN Inhibition by Omeprazole in Combination With Cabazitaxel in Patients With Docetaxel- and Castration-Resistant Prostate Cancer
Conditions
Interventions
Omeprazole 80 mg twice daily
Locations
2
United States
W.G. Bill Hefner VA Medical Center
Salisbury, North Carolina, United States
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Start Date
March 5, 2021
Primary Completion Date
February 1, 2028
Completion Date
March 1, 2028
Last Updated
April 13, 2026
NCT06844383
NCT06926283
NCT07177937
NCT06594926
NCT05919264
NCT06487507
Lead Sponsor
Wake Forest University Health Sciences
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions